Yuanyuan Duan

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy et al. · The Lancet · 2022 · 126 citations · Full text

Rheumatology, Spondyloarthritis, Inflammatory Rheumatic Disease +4

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

Iain B. McInnes, Koji Kato, Marina Magrey et al. · RMD Open · 2021 · 85 citations · Full text

Age and Mothers: Potent Influences of Children’s Skin Microbiota

Ting Zhu, Xing Liu, Fanqi Kong et al. · Journal of Investigative Dermatology · 2019 · 84 citations

Microbiome Biology, Microbiota Function, Potent Influences +11

Change in skin properties over the first 10 years of life: a cross-sectional study

Fanqi Kong, Carlos Galzote, Yuanyuan Duan · Archives of Dermatological Research · 2017 · 60 citations · Full text

Dermatology, Body Composition, Longevity +17

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

Désirée van der Heijde, Atul Deodhar, Walter P. Maksymowych et al. · RMD Open · 2022 · 45 citations · Full text